Tony, I figure a partnership should be a positive as long as the upfronts aren't $5 mil range or less. The way I'm looking at it, $8 mil could be considered decent, and $10 mil or more good, but it depends on what we have to give up. I'd like to see RD/SA partnered off, with Cortex keeping CX-1739/ADHD. But to get good upfronts will probably mean partnering away CX-1739/ADHD, leaving Cortex without a clinic ready compound for a while.
The bigger near term problem for me is the timing of the delisting appeal news. From what I could glean, it should come within 45 days of the appeal request, which was approx Aug 27, so that would make it by Oct 11. But this is a fuzzy estimate since if Cortex has a deal close to completion, the AMEX panel might allow an extension (?) The SA trial news can also be problematic, though there's also a chance it could be favorable.
If we get the bad news out of the way before the good, I may get back in. But of course the expected bad news might not come (delisting appeal), or could turn out to be good/benign (SA results), or the good news might come sooner (partnership), though the good news might actually turn out to be bad on balance (poor upfronts).
Anyway, the whole thing is giving me a headache :o)
Market Data 
Markets 
AI
